Tumor-associated calcium signal transducer 2 (TROP2) is a promising molecular target for TROP2-expressing malignancies, including NSCLC. Datopotamab deruxtecan and sacituzumab govitecan are TROP2-targeted antibody-drug conjugates (ADCs) currently in development for clinical use. Explore the clinical trial data and listen to faculty perspectives regarding the potential use of these emerging agents in the treatment of NSCLC.
TROP2
The HOPE for NSCLC Learning Center is an educational resource developed by Paradigm Medical Communications in collaboration with The American Lung Association. The Learning Center, which features multiple individually accredited CME activities and patient and clinician resources, is for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.
For questions or technical support please email us at contactus@paradigmmc.com.